| Active substance | Vericiguat |
| Holder | Bayer |
| Status | closed |
| Indication | Adult patients with symptomatic chronic heart failure (New York Heart Association (NYHA) Class II-III-IV) with a reduced ejection fraction who are stabilized after a previous decompensation event requiring IV therapy. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Lastupdate | 26/06/2023 |